ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 1324 • ACR Convergence 2023

    Previous History of Serious Infection Is Associated with the Use of IL-6 Inhibitors in Rheumatoid Arthritis in Wales, UK

    Roxanne Cooksey1 and Ernest Choy2, 1Cardiff University, Cardiff, United Kingdom, 2Section of Rheumatology, Cardiff University, Cardiff, United Kingdom

    Background/Purpose: Biologic therapy has revolutionised the treatment of rheumatoid arthritis (RA). Randomised control trials have shown that IL-6 inhibitors are superior to adalimumab, a TNF…
  • Abstract Number: 1340 • ACR Convergence 2023

    Recent Trends in Treatment Patterns for Rheumatoid Arthritis in Response to Emerging Data

    Stephanie Song1, Michael George2, Ted R Mikuls3, Bryant England4, Brian Sauer5, Grant Cannon6 and Joshua Baker2, 1Hospital of the University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, 3Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, 4University of Nebraska Medical Center, Omaha, NE, 5Salt Lake City VA/University of Utah, Salt Lake City, UT, 6University of Utah and Salt Lake City VA, Salt Lake City, UT

    Background/Purpose: Janus kinase inhibitors (JAKi) have demonstrated substantial efficacy in decreasing symptoms and in reducing progressive joint damage in patients with rheumatoid arthritis (RA). In…
  • Abstract Number: 1629 • ACR Convergence 2023

    Persons with Rheumatoid Arthritis and Long COVID Had Worse Pre-COVID RA Symptoms and Worse Non-RA Symptoms, as Well as Higher Rates of Fibromyalgia Compared with COVID Infected Long COVID Negative

    Kaleb Michaud1, Sofia Pedro2, Shreena Kamlesh Gandhi3 and Frederick Wolfe2, 1University of Nebraska Medical Center, Omaha, NE, 2Forward, The National Databank for Rheumatic Diseases, Wichita, KS, 3Kansas University School of Medicine, Wichita, KS

    Background/Purpose: Long COVID, also known as Post COVID syndrome or postacute sequelae of SARS-CoV-2 infection, refers to the development of persistent or new symptoms lasting…
  • Abstract Number: 1723 • ACR Convergence 2023

    3,3-dimethyl-1-butanol and Its Metabolite 3,3-dimethylbutyrate Ameliorate Arthritis Severity in CIA Independent of Choline TMA Lyase Activity

    Brendan Allen1, Sabrina Fechtner2, Meagan Chriswell3, Widian Jubair1, M. Aaron Vrolijk1, V. Michael Holers4 and kristine Kuhn1, 1University of Colorado School of Medicine, Aurora, CO, 2University of Colorado Anschutz Medical Campus, Aurora, CO, 3University of Colorado Anschutz SOM, Denver, CO, 4University of Colorado, Denver, CO

    Background/Purpose: Both human and animal studies associate specific microbiota and microbial metabolic pathways with the development of RA and autoimmune arthritis, thereby providing a novel…
  • Abstract Number: 1741 • ACR Convergence 2023

    The Occurrence and Phenotype of Autoreactive T Cells in the At-Risk Phase of Rheumatoid Arthritis

    Sara Turcinov1, Charlotte de Vries2, Ravi Kumar Sharma2, Christina Gerstner2, Bruno Raposo2, Anatoly Dubnovitsky2, William Kwok3, Karine Chemin2, Vivianne Malmström4 and Aase Hensvold5, 1Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet. Theme of Inflammation and Ageing, Medical Unit Gastro, Derma, Rheuma, Karolinska University Hospital, Stockholm, Sweden, 2Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 3Benaroya Research Institute at Virginia Mason, Seattle, WA, 4Karolinska Institutet, Stockholm, Sweden, 5Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet. Center for Rheumatology, Academic Specialist Center, Stockholm, Sweden

    Background/Purpose: CD4+ T cells recognizing citrullinated epitopes are present in peripheral blood of anti-citrulline protein antibody (ACPA) positive rheumatoid arthritis (RA) patients at time of…
  • Abstract Number: 1757 • ACR Convergence 2023

    Quantitative Assessment of Synovial Vascularity Using Power Doppler Index in Rheumatoid Arthritis and Psoriatic Arthritis Patients with High Disease Activity

    Michał Jakubaszek, Maria Maślińska and Brygida Kwiatkowska, National Institute of Geriatrics Rheumatology and Rehabilitation, Warsaw, Poland

    Background/Purpose: Usefulness of quantitative assessment of synovial vascularity in ultrasound (US) imaging in patients with active RA and PsA (peripheral arthritis). Additionally the assessment of…
  • Abstract Number: 1773 • ACR Convergence 2023

    Integrated Analysis of Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes (FLS) Transcriptome and Chromatin Accessibility Identifies Mechanisms Associated with Location-specific Disease Severity

    Eunice Choi1, Camilla R. L. Machado2, David Boyle1, Wei Wang1 and Gary Firestein2, 1University of California San Diego, La Jolla, CA, 2University of California San Diego, San Diego, CA

    Background/Purpose: Mechanisms responsible for the distribution and severity of joint involvement in RA are not known. To explore whether site-specific FLS biology might contribute to…
  • Abstract Number: 1895 • ACR Convergence 2023

    Comparative Analysis of Existing Tools in Assessing Cardiovascular Risk in Patients with Rheumatoid Arthritis: Exploring the Inadequacies

    Pritee Shrestha1, Peter Larsen1 and Pablo Weilg Espejo2, 1Mercy One North Iowa Medical Center, Mason City, IA, 2Boston Medical Center, Chelsea, MA

    Background/Purpose: Patients with Rheumatoid Arthritis (RA) are at increased risk of cardiovascular disease (CVD). Despite multiple CVD risk tools available, reliability to RA population is…
  • Abstract Number: 2092 • ACR Convergence 2023

    Feasibility and Efficacy of Culturally Appropriate Spanish Language-First Patient Education for Rheumatoid Arthritis

    Daniel Hernandez1, Julio Bravo2, Juan Maya Villamizar3, Oscar Soto4, Angel Tapia5, Guillermo Valenzuela6, W. Benjamin Nowell7 and Shilpa Venkatachalam8, 1Global Healthy Living Foundation, St. Johns, FL, 2Novant, Winston-Salem, NC, 3Rheumatology Center of Palm Beach, PLLC, Boca Raton, FL, 4Mindful Rheumatix and Medical Research Group, San Juan, PR, 5Global Healthy Living Foundation, Upper Nyack, NY, 6Integral Rheumatology & Immunology Specialists, Plantation, FL, 7Global Healthy Living Foundation, Nyack, NY, 8Global Healthy Living Foundation, New York, NY

    Background/Purpose: Spanish-speaking patients with rheumatic arthritis (RA) need RA education that is medically accurate, conversational, and engaging. Our study examined the feasibility and efficacy of…
  • Abstract Number: 2111 • ACR Convergence 2023

    Self-reported Methotrexate Adherence Underestimates Biochemical Adherence: Results from the Methotrexate Use Improvement in Rheumatoid Arthritis Using Biomarker Feedback Trial

    James Bluett1, Kimme Hyrich2, Brian Keevil3, Patty Doran4 and Anne Barton5, 1University of Manchester, Manchester, United Kingdom, 2Versus Arthritis Centre for Epidemiology, Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, 3Department of Clinical Biochemistry, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, 4School of Social Sciences, The University of Manchester, Manchester, United Kingdom, 5Versus Arthritis Centre for Genetics and Genomics, Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom

    Background/Purpose: Methotrexate (MTX) adherence is suboptimal and is associated with disease flare, DAS-28 response, radiographic damage and healthcare costs. Adherence can be measured using self-reported…
  • Abstract Number: 2127 • ACR Convergence 2023

    Associations Between Rheumatoid Arthritis, Frailty Status and Mortality in Older Adults with Bladder Cancer

    Maya Swaminathan1, Sarah Holt2, John Gore2, Yaw Nyame2, Jonathan Wright2, George Schade2, Ami Shah3, Jeffrey Sparks4, Una Makris5, Petros Grivas6, Maria Suarez-Almazor7, Sarah Psutka2 and Namrata Singh8, 1University of Washington, Seattle, WA, 2Department of Urology, University of Washington, Seattle, WA, 3Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, 4Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 5UT Southwestern Medical Center and Dallas VA, Dallas, TX, 6Division of Medical Oncology, Dept. of Medicine, UW; Clinical Research Division; Fred Hutchinson Cancer Center, Seattle, WA, 7MD Anderson Cancer Center, Houston, TX, 8University of Washington, Bellevue, WA

    Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of developing certain cancers, including bladder cancer (Beydon et al. 20231). However, few studies have…
  • Abstract Number: 2143 • ACR Convergence 2023

    Efficacy of Filgotinib in Patients with Rheumatoid Arthritis: Week 156 Results from a Long-term Extension Study

    Maya Buch1, Daniel Aletaha2, Roberto F. Caporali3, Bernard G. Combe4, Hendrik Schulze-Koops5, Jacques-Eric Gottenberg6, Yoshiya Tanaka7, Ricardo Blanco8, Tsutomu Takeuchi9, Edmund V. Ekoka Omoruyi10, Katrien Van Beneden11, Vijay Rajendran12, Chris Watson13, Francesco De Leonardis14 and Paul Emery15, 1University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, 2Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, Wien, Austria, 3Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milano, Italy, 4Department of Rheumatology, Montpellier University, Montpellier, France, 5Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, Ludwig-Maximilians–University Munich, Munich, Germany, 6Rheumatology Department, Strasbourg University Hospital, Strasbourg, France, 7University of Occupational and Environmental Health, Kitakyushu, Japan, 8Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 9Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, 10Biostatistics, Galapagos NV, Mechelen, Belgium, 11Medical Safety, Galapagos NV, Mechelen, Belgium, 12Clinical Research, Galapagos NV, Mechelen, Belgium, 13Medical Affairs, Galapagos Biotech Ltd., Cambridge, United Kingdom, 14Medical Affairs, Galapagos GmbH, Basel, Switzerland, 15Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    Background/Purpose: In the treatment of RA, JAK inhibitors are a valuable option to meet remission or low disease activity (LDA) treatment targets following an inadequate…
  • Abstract Number: 2159 • ACR Convergence 2023

    Results of a 24-week Open-label, Non-interventional Study of the Efficacy and Safety of Olokizumab Therapy in Patients with Rheumatoid Arthritis After Switching from Anti-B-cell Therapy During the SARS-COV-2 Pandemic

    Sofia Kuzkina1, Eugen Feist2, Nadezhda E. Banshchikova3, Anna A. Akimova3, Alexey E. Sizikov4, Arsen A. Mullagaliev3, Nadezhda A. Ilina4, Elena A. Letyagina3 and Maxim A. Korolev3, 1R-Pharm, Moscow, Russia, 2Helios Department of Rheumatology and Clinical Immunology, Vogelsang-Gommern, Germany, 3Research Institute of Clinical and Experimental Lymphology – branch of Federal State Budget Scientific Institution « Federal Research Center “Institute of cytology and genetics of Siberian Branch of Russian Academy of Sciences", Novosibirsk, Russia, 4Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia

    Background/Purpose: The COVID-19 pandemic has significantly changed the understanding of the safety profile of therapies for immunoinflammatory rheumatic diseases. This is primarily due to the…
  • Abstract Number: 2176 • ACR Convergence 2023

    Cellular and Proteomic Changes Following Administration of Peresolimab, in a Phase 2a Trial in Rheumatoid Arthritis

    Robert J. Benschop1, Jay Tuttle1, Paul Emery2, Christoph Preuss1, Mark Daniels1, Veavi Ching-Yun Chan1, Pia Yachi1 and Ajay Nirula1, 1Eli Lilly and Company, Indianapolis, IN, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    Background/Purpose: Peresolimab is a humanized immunoglobulin G1 monoclonal antibody that stimulates human programmed cell death protein 1 (PD-1). Peresolimab demonstrated superiority to placebo in Disease…
  • Abstract Number: 2480 • ACR Convergence 2023

    Definition of Rheumatoid Arthritis Flare Based on SDAI and CDAI

    Victoria Konzett1, Andreas Kerschbaumer2, Josef S Smolen3, Eirik Kristianslund4, Sella Provan4, Tore Kvien5 and Daniel Aletaha6, 1Medical University of Vienna, Wien, Austria, 2Medical University of Vienna, Vienna, Austria, 3Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, 4Diakonhjemmet Hospital, Oslo, Norway, 5Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, 6Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, Wien, Austria

    Background/Purpose: Measures of improvement and state of disease activity are well-established in rheumatoid arthritis (RA), whereas distinct classifiers for worsening (“flare”) are lacking to date.…
  • « Previous Page
  • 1
  • …
  • 48
  • 49
  • 50
  • 51
  • 52
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology